Energenesis Biomedical Co (TPE:6657) Long-Term Debt: NT$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6657 Energenesis Biomedical Co Ltd TPE:6657
64 GF Score
Price NT$34.00
GF Value NT$51.53
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Energenesis Biomedical Co Long-Term Debt?

Energenesis Biomedical Co TPE:6657 -5.16% 64 Long-Term Debt is NT$0.00 Mil as of Dec. 2025. GuruFocus rates TPE:6657 with a GF Score™ of 64/100 and a GF Value™ of NT$51.53 (Possible Value Trap). The stock has 3 warning signs investors should review.

Energenesis Biomedical Co's Long-Term Debt for the quarter that ended in Dec. 2025 was NT$0.00 Mil.

Energenesis Biomedical Co  (TPE:6657) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Energenesis Biomedical Co Long-Term Debt Related Terms

Energenesis Biomedical Co Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Energenesis Biomedical Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Energenesis Biomedical Co Long-Term Debt Chart

Energenesis Biomedical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Energenesis Biomedical Co Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TPE:6657
64GF Score
Energenesis Biomedical Co Ltd TPE:6657
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of NT$0.00 Mil mean?
Energenesis Biomedical Co (TPE:6657) has a Long-Term Debt of NT$0.00 Mil as of Dec. 2025.
Is Energenesis Biomedical Co's Long-Term Debt too high?
Energenesis Biomedical Co's current Long-Term Debt is NT$0.00 Mil. Overall, Energenesis Biomedical Co has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Energenesis Biomedical Co's Long-Term Debt compare to VRTX and REGN?
Energenesis Biomedical Co's Long-Term Debt of NT$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Energenesis Biomedical Co's current Long-Term Debt is NT$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Energenesis Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Energenesis Biomedical Co (TPE:6657) is currently considered Possible Value Trap. The stock's GF Value™ is NT$51.53, compared to a current price of NT$34.00 — trading 34% below its estimated fair value. The current Long-Term Debt is NT$0.00 Mil. Energenesis Biomedical Co's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Energenesis Biomedical Co (TPE:6657), the current Long-Term Debt is NT$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Energenesis Biomedical Co (TPE:6657) Overvalued in 2026?

Based on GuruFocus' analysis, Energenesis Biomedical Co stock appears to be undervalued. The current stock price of NT$34.00 is trading 34% below its estimated GF Value™ of NT$51.53. GuruFocus considers Energenesis Biomedical Co to be Possible Value Trap.

Key valuation signals for TPE:6657:

  • Long-Term Debt: NT$0.00 Mil
  • GF Value™: NT$51.53 vs. price of NT$34.00 (34% below fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the TPE:6657 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Energenesis Biomedical Co Business Description

Address No. 21, Lane 583, Ruiguang Road, 6th Floor -3, Neihu District, Taipei, TWN, 11492
Energenesis Biomedical Co Ltd is a biomedicine company. The company is engaged in businesses related to biological experimentation and analysis, as well as new drugs development. The company uses its ENERGI drug development platform to activate AMP-activated protein kinase (AMPK), a key enzyme in cell energy regulation, as a means of developing disease treatments. The product pipeline of the company consists of ENERGI-F703, a diabetic foot ulcers treatment gel; ENERGI-F701, a product developed for male hair loss; ENERGI-F704, an inflammatory bowel disease treatment; and ENERGI-F711, a burn cream,F708, Asthama treatment, and others.
64GF Score

Get the complete analysis for TPE:6657

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$34.00
Price
NT$51.53
GF Value